HealthDay (1/7, Gotkine) reports, “Dried blood collection derived from capillary blood shows potential for Alzheimer disease (AD) biomarker testing, according to a study.” Researchers “examined the potential of dried plasma spot (DPS) and dried blood spot (DBS) analysis, derived from capillary blood, for detecting AD biomarkers, including phosphorylated tau at amino acid 217 (p-tau217), glial fibrillary acidic protein, and neurofilament light.” The investigators “identified strong correlations between DPS p-tau217 and venous plasma p-tau217. There was a progressive increase in DPS p-tau217 with increasing disease severity, with good accuracy for predicting cerebrospinal fluid biomarker positivity.” By “using paired venous plasma samples, glial fibrillary acidic protein and neurofilament light were successfully detected, with strong correlations between DBS and DPS, respectively.” The findings were published in Nature Medicine.

Related Links:

— “Dried Blood Collection Shows Potential for Alzheimer Disease Biomarker Testing,”Elana Gotkine, HealthDay , January 7, 2026